eine kleine aktuelle Übersicht. MOR kommt im Erfolgsfall später auf einen Markt mit mehreren Alternativprodukten. --- ...Currently, only 2 agents, ruxolitinib (Jakafi) and fedratinib (Inrebic) are FDA approved for use in patients with myelofibrosis.
However, the field is rich with emerging agents that will change treatment patterns, Gerds explains. For example, the JAK inhibitors pacritinib and momelotinib are likely to be FDA approved within a year. Moreover, a press release reported that pivotal phase 3 MOMENTUM trial (NCT04173494), which is evaluating momelotinib vs danazol in patients with myelofibrosis who are symptomatic and anemic, met its primary end point, as well as all key secondary end points.
Other agents, such as the BET inhibitor pelabresib and the BCL-2 inhibitor navitoclax, are emerging for use in myelofibrosis, Gerds says. Ultimately, these novel agents are targeting pathways that are independent of the JAK/STAT pathway, which is traditionally used to augment responses in myelofibrosis, Gerds concludes.
|